Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716981 | 1.00 | KMT2A (0.32) | KMT2AMEN1MAPTGAANPC1 | |
| SCHEMBL716983 | 1.00 | KMT2A (0.32) | KMT2AMEN1MAPTGAANPC1 | |
| SCHEMBL716982 | 1.00 | KMT2A (0.32) | KMT2AMEN1MAPTGAANPC1 | |
| SCHEMBL19331535 | 0.84 | MAPT (0.36) | KMT2AMEN1MAPTGAANPC1 | |
| SCHEMBL19331536 | 0.84 | MAPT (0.36) | KMT2AMEN1MAPTGAANPC1 | |
| SCHEMBL721697 | 0.82 | ALDH1A1 (0.34) | KMT2AMEN1MAPTGAANPC1 | |
| SCHEMBL721694 | 0.82 | ALDH1A1 (0.34) | KMT2AMEN1MAPTGAANPC1 | |
| SCHEMBL721695 | 0.82 | ALDH1A1 (0.34) | KMT2AMEN1MAPTGAANPC1 | |
| SCHEMBL721696 | 0.82 | ALDH1A1 (0.34) | KMT2AMEN1MAPTGAANPC1 | |
| SCHEMBL2116469 | 0.81 | MAPT (0.48) | KMT2AMEN1MAPTGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8957090-B2 | Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2015-02-17 | — | — | US | disclosed |
| EP-2499126-B1 | FUSED BICYCLIC PYRIDINE AND PYRAZINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2015-01-07 | — | — | EP | disclosed |
| EP-2499129-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-07-30 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-8653105-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-02-18 | — | — | US | disclosed |
| EP-2499144-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20130012515-A1 | Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | disclosed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | KMT2A 1670/4885MEN1 3000/4885MAPT 1229/4885 |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | KMT2A 2560/4885MEN1 3086/4885MAPT 1748/4885 |
| US-20130012515-A1 | Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors | MAP3K13, MAP3K15, MAP3K12 | KMT2A 2748/4885MEN1 3445/4885MAPT 1705/4885 |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | KMT2A 4018/4885MEN1 3999/4885MAPT 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.